Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03307785
Recruitment Status : Active, not recruiting
First Posted : October 12, 2017
Results First Posted : May 10, 2021
Last Update Posted : May 10, 2021
Sponsor:
Information provided by (Responsible Party):
Tesaro, Inc.

Brief Summary:

Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part B: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part C: To test the safety and tolerability of combination therapy with Niraparib, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study.

Part D: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study.

Part E: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part F: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part G: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part H: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part I: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.


Condition or disease Intervention/treatment Phase
Neoplasms Metastatic Cancer Advanced Cancer Solid Tumor Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer Stage IIIB Non Small Cell Lung Cancer Drug: Niraparib Drug: TSR-042 Drug: Carboplatin-Paclitaxel Drug: Bevacizumab Drug: TSR-022 Drug: Carboplatin-Pemetrexed Drug: Carboplatin-Nab-Paclitaxel Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Actual Study Start Date : October 12, 2017
Actual Primary Completion Date : February 26, 2020
Estimated Study Completion Date : November 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part A: TSR-042 and niraparib 200 mg QD
Patients will receive TSR-042 500 milligram (mg), intravenous (IV) infusion on Day 1 of every cycle (every 3 weeks [Q3W]) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (every 6 weeks [Q6W]) beginning on Day 1 of Cycle 5 along with niraparib 200 mg, once daily (QD), orally on Days 1 to 21 repeated Q3W.
Drug: Niraparib
Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
Other Name: Zejula

Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Experimental: Part A: TSR-042 and niraparib 300 mg QD
Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg, QD, orally on Days 1 to 21 repeated Q3W.
Drug: Niraparib
Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
Other Name: Zejula

Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Experimental: Part B: TSR-042 and carboplatin-paclitaxel
Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 milligram per square meter (mg/m^2), IV infusion on Day 1 Q3W administered for 4 to 6 cycles.
Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Drug: Carboplatin-Paclitaxel
Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer [NSCLC], ovarian cancer, endometrial cancer, and head and neck cancer.

Experimental: Part C: TSR-042, niraparib 200 mg QD and bevacizumab
Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 200 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kilogram (kg), IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
Drug: Niraparib
Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
Other Name: Zejula

Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Drug: Bevacizumab
Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
Other Name: Avastin

Experimental: Part C: TSR-042, niraparib 300 mg QD and bevacizumab
Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
Drug: Niraparib
Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
Other Name: Zejula

Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Drug: Bevacizumab
Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
Other Name: Avastin

Experimental: Part D: TSR-042, carboplatin-paclitaxel and bevacizumab
Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m^2, IV infusion on Day 1 Q3W administered for 4 to 6 cycles; and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Drug: Carboplatin-Paclitaxel
Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer [NSCLC], ovarian cancer, endometrial cancer, and head and neck cancer.

Drug: Bevacizumab
Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
Other Name: Avastin

Experimental: Part E: TSR-042 and carboplatin-pemetrexed
Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W and pemetrexed 500 mg/m^2, IV infusion on Day 1 Q3W (with vitamin supplementation) administered for 6 cycles (each cycle is 21 days).
Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Drug: Carboplatin-Pemetrexed
Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients

Experimental: Part F: TSR-042, TSR-022, and carboplatin-pemetrexed
Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); and TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W administered for 5 cycles (each cycle is 21 days); and pemetrexed 500 mg/m^2, IV infusion on Day 1 Q3W (with vitamin supplementation).
Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Drug: TSR-022

TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.

TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth.


Drug: Carboplatin-Pemetrexed
Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients

Experimental: Part G: TSR-042 and carboplatin-nab-paclitaxel
Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m^2, IV infusion on Days 1, 8 and 15 (every week [Q1W]) of every 3 week cycle for 4 to 6 cycles.
Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Drug: Carboplatin-Nab-Paclitaxel
Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.

Experimental: Part H: TSR-042, TSR-022, and carboplatin-nab-paclitaxel
Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m^2, IV infusion on Days 1, 8 and 15 (Q1W) of every 3 week cycle for 4 to 6 cycles.
Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Drug: TSR-022

TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.

TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth.


Drug: Carboplatin-Nab-Paclitaxel
Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.

Experimental: Part I: TSR-042, TSR-022, and carboplatin-paclitaxel
Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m^2, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days).
Drug: TSR-042
TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

Drug: Carboplatin-Paclitaxel
Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer [NSCLC], ovarian cancer, endometrial cancer, and head and neck cancer.

Drug: TSR-022

TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.

TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth.





Primary Outcome Measures :
  1. Part A: Number of Participants With Dose-limiting Toxicity (DLT) [ Time Frame: 21 days ]
    An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for >=7 days from the time of adverse event(AE) onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for >=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for >=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish recommended phase 2 dose (RP2D).

  2. Part B: Number of Participants With DLT [ Time Frame: 21 days ]
    An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for >=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for >=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for >=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish RP2D.

  3. Part C: Number of Participants With DLT [ Time Frame: 21 days ]
    An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for >=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for >=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for >=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish RP2D.

  4. Part D: Number of Participants With DLT [ Time Frame: 21 days ]
    An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for >=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for >=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for >=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish RP2D.

  5. Part E: Number of Participants With DLT [ Time Frame: 21 days ]
    An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for >=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for >=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for >=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish RP2D.

  6. Part F: Number of Participants With DLT [ Time Frame: 21 days ]
    An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for >=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for >=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for >=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish RP2D.

  7. Part G: Number of Participants With DLT [ Time Frame: 21 days ]
    An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for >=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for >=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for >=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (>2 weeks) in initiating Cycle 2. DLTs were planned to be collected during first cycle to establish RP2D.

  8. Part H: Number of Participants With DLT [ Time Frame: 21 days ]
    An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for >=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for >=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for >=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (>2 weeks) in initiating Cycle 2. DLTs were planned to be collected during first cycle to establish RP2D.

  9. Part I: Number of Participants With DLT [ Time Frame: 21 days ]
    An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for >=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for >=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for >=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (>2 weeks) in initiating Cycle 2. DLTs were planned to be collected during first cycle to establish RP2D.

  10. Part A: Number of Participants With Non-serious Treatment-emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs) and Adverse Events of Special Interest (AESIs) [ Time Frame: Up to 28.5 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported.

  11. Part B: Number of Participants With Non-serious TEAEs, STEAEs and AESIs [ Time Frame: Up to 28.5 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported.

  12. Part C: Number of Participants With Non-serious TEAEs, STEAEs and AESIs [ Time Frame: Up to 22.5 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported.

  13. Part D: Number of Participants With Non-serious TEAEs, STEAEs and AESIs [ Time Frame: Up to 9.5 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported.

  14. Part E: Number of Participants With Non-serious TEAEs, STEAEs and AESIs [ Time Frame: Up to 4.4 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported.

  15. Part F: Number of Participants With Non-serious TEAEs, STEAEs and AESIs [ Time Frame: Up to 3.5 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported.

  16. Part G: Number of Participants With Non-serious TEAEs, STEAEs and AESIs [ Time Frame: Up to 24 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

  17. Part H: Number of Participants With Non-serious TEAEs, STEAEs and AESIs [ Time Frame: Up to 24 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

  18. Part I: Number of Participants With Non-serious TEAEs, STEAEs and AESIs [ Time Frame: Up to 24 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.


Secondary Outcome Measures :
  1. Part A: Objective Response Rate [ Time Frame: Up to 28.5 months ]
    Objective Response Rate is defined as the percentage of participants who achieved confirmed complete response (CR) or partial response (PR), evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 millimeters (mm) in the short axis. PR=At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

  2. Part B: Objective Response Rate [ Time Frame: Up to 28.5 months ]
    Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

  3. Part C: Objective Response Rate [ Time Frame: Up to 22.5 months ]
    Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

  4. Part D: Objective Response Rate [ Time Frame: Up to 9.5 months ]
    Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

  5. Part E: Objective Response Rate [ Time Frame: Up to 4.4 months ]
    Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

  6. Part F: Objective Response Rate [ Time Frame: Up to 3.5 months ]
    Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

  7. Part G: Objective Response Rate [ Time Frame: Up to 24 months ]
    Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

  8. Part H: Objective Response Rate [ Time Frame: Up to 24 months ]
    Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

  9. Part I: Objective Response Rate [ Time Frame: Up to 24 months ]
    Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

  10. Part A: Duration of Response [ Time Frame: Up to 28.5 months ]
    Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause.

  11. Part B: Duration of Response [ Time Frame: Up to 28.5 months ]
    Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause. Data is not reported as participants response is still ongoing at the time of primary analysis.

  12. Part C: Duration of Response [ Time Frame: Up to 22.5 months ]
    Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause. Data is not reported as participants response is still ongoing at the time of primary analysis.

  13. Part D: Duration of Response [ Time Frame: Up to 9.5 months ]
    Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause. Data is not reported as participants response is still ongoing at the time of primary analysis.

  14. Part E: Duration of Response [ Time Frame: Up to 4.4 months ]
    Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause.

  15. Part F: Duration of Response [ Time Frame: Up to 3.5 months ]
    Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause.

  16. Part G: Duration of Response [ Time Frame: Up to 24 months ]
    Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause.

  17. Part H: Duration of Response [ Time Frame: Up to 24 months ]
    Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause.

  18. Part I: Duration of Response [ Time Frame: Up to 24 months ]
    Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause.

  19. Part A: Disease Control Rate [ Time Frame: Up to 28.5 months ]
    Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or stable disease (SD) per RECIST version 1.1.

  20. Part B: Disease Control Rate [ Time Frame: Up to 28.5 months ]
    Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1.

  21. Part C: Disease Control Rate [ Time Frame: Up to 22.5 months ]
    Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1.

  22. Part D: Disease Control Rate [ Time Frame: Up to 9.5 months ]
    Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1.

  23. Part E: Disease Control Rate [ Time Frame: Up to 4.4 months ]
    Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1.

  24. Part F: Disease Control Rate [ Time Frame: Up to 3.5 months ]
    Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1.

  25. Part G: Disease Control Rate [ Time Frame: Up to 24 months ]
    Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1.

  26. Part H: Disease Control Rate [ Time Frame: Up to 24 months ]
    Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1.

  27. Part I: Disease Control Rate [ Time Frame: Up to 24 months ]
    Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1.

  28. Part A: Progression-free Survival [ Time Frame: Up to 28.5 months ]
    Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

  29. Part B: Progression-free Survival [ Time Frame: Up to 28.5 months ]
    Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

  30. Part C: Progression-free Survival [ Time Frame: Up to 22.5 months ]
    Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

  31. Part D: Progression-free Survival [ Time Frame: Up to 9.5 months ]
    Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

  32. Part E: Progression-free Survival [ Time Frame: Up to 4.4 months ]
    Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

  33. Part F: Progression-free Survival [ Time Frame: Up to 3.5 months ]
    Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

  34. Part G: Progression-free Survival [ Time Frame: Up to 24 months ]
    Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier.

  35. Part H: Progression-free Survival [ Time Frame: Up to 24 months ]
    Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier.

  36. Part I: Progression-free Survival [ Time Frame: Up to 24 months ]
    Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier.

  37. Part A: Number of Participants With Positive Anti-TSR-042 Antibodies [ Time Frame: Up to 28.5 months ]
    Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay). Anti-drug Antibody Population consisted of all participants who received at least 1 dose of study treatment and had provided a pre-dose blood sample and at least 1 post-dose blood sample at or after 96 hours.

  38. Part B: Number of Participants With Positive Anti-TSR-042 Antibodies [ Time Frame: Up to 28.5 months ]
    Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  39. Part C: Number of Participants With Positive Anti-TSR-042 Antibodies [ Time Frame: Up to 22.5 months ]
    Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  40. Part D: Number of Participants With Positive Anti-TSR-042 Antibodies [ Time Frame: Up to 9.5 months ]
    Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  41. Part E: Number of Participants With Positive Anti-TSR-042 Antibodies [ Time Frame: Up to 4.4 months ]
    Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  42. Part F: Number of Participants With Positive Anti-TSR-042 Antibodies [ Time Frame: Up to 3.5 months ]
    Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  43. Part F: Number of Participants With Positive Anti-TSR-022 Antibodies [ Time Frame: Up to 3.5 months ]
    Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-022. The presence of anti-TSR-022 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  44. Part G: Number of Participants With Positive Anti-TSR-042 Antibodies [ Time Frame: Up to 24 months ]
    Serum samples were planned to be collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were planeed to be assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  45. Part H: Number of Participants With Positive Anti-TSR-042 Antibodies [ Time Frame: Up to 24 months ]
    Serum samples were planned to be collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were planned to be assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  46. Part H: Number of Participants With Positive Anti-TSR-022 Antibodies [ Time Frame: Up to 24 months ]
    Serum samples were planned to be collected at indicated time points and tested for the presence of antibodies that bind to TSR-022. The presence of anti-TSR-022 antibodies were planned to be assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  47. Part I: Number of Participants With Positive Anti-TSR-042 Antibodies [ Time Frame: Up to 24 months ]
    Serum samples were planned to be collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were planned to be assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  48. Part I: Number of Participants With Positive Anti-TSR-022 Antibodies [ Time Frame: Up to 24 months ]
    Serum samples were planned to be collected at indicated time points and tested for the presence of antibodies that bind to TSR-022. The presence of anti-TSR-022 antibodies were planned to be assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay).

  49. Part A: Area Under the Plasma Concentration From Time Zero to t (AUC[0-t]) of Niraparib [ Time Frame: Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. Pharmacokinetic (PK) parameters of niraparib were calculated using non-compartmental methods. PK population consisted of all participants who received at least 1 dose of study treatment and had at least 1 PK sample.

  50. Part A: AUC(0-t) of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  51. Part B: AUC0-t of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  52. Part C: AUC0-t of Niraparib [ Time Frame: Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  53. Part C: AUC0-t of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  54. Part D: AUC0-t of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  55. Part E: AUC0-t of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  56. Part F: AUC0-t of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  57. Part F: AUC0-t of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  58. Part G: AUC0-t of TSR-042 [ Time Frame: Cycles 1 and 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  59. Part H: AUC0-t of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  60. Part H: AUC0-t of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  61. Part I: AUC0-t of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  62. Part I: AUC0-t of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  63. Part A: Area Under the Plasma Concentration From Time Zero to Infinity (AUC[0-infinity]) of Niraparib [ Time Frame: Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  64. Part A: AUC(0-infinity) of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  65. Part B: AUC(0-infinity) of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  66. Part C: AUC(0-infinity) of Niraparib [ Time Frame: Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  67. Part C: AUC(0-infinity) of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  68. Part D: AUC(0-infinity) of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  69. Part E: AUC(0-infinity) of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  70. Part F: AUC(0-infinity) of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  71. Part F: AUC(0-infinity) of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  72. Part G: AUC(0-infinity) of TSR-042 [ Time Frame: Cycles 1 and 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  73. Part H: AUC(0-infinity) of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  74. Part H: AUC(0-infinity) of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  75. Part I: AUC(0-infinity) of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  76. Part I: AUC(0-infinity) of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  77. Part A: Observed Concentration at the End of the Dosing Interval (Ctau) of Niraparib [ Time Frame: Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  78. Part A: Ctau of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  79. Part B: Ctau of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  80. Part C: Ctau of Niraparib [ Time Frame: Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  81. Part C: Ctau of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  82. Part D: Ctau of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  83. Part E: Ctau of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  84. Part F: Ctau of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  85. Part F: Ctau of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  86. Part G: Ctau of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  87. Part H: Ctau of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  88. Part H: Ctau of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  89. Part I: Ctau of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  90. Part I: Ctau of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  91. Part A: Maximum Observed Plasma (Cmax) of Niraparib [ Time Frame: Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  92. Part A: Cmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  93. Part B: Cmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  94. Part C: Cmax of Niraparib [ Time Frame: Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  95. Part C: Cmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  96. Part D: Cmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  97. Part E: Cmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  98. Part F: Cmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  99. Part F: Cmax of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  100. Part G: Cmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  101. Part H: Cmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  102. Part H: Cmax of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  103. Part I: Cmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  104. Part I: Cmax of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  105. Part A: Clearance After Oral Administration (CL/F) of Niraparib [ Time Frame: Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  106. Part A: Clearance After Intravenous Administration (CL) of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  107. Part B: CL of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  108. Part C: CL/F of Niraparib [ Time Frame: Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  109. Part C: CL of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  110. Part D: CL of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  111. Part E: CL of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  112. Part F: CL of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  113. Part F: CL of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  114. Part G: CL of TSR-042 [ Time Frame: Cycles 1 and 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  115. Part H: CL of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  116. Part H: CL of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  117. Part I: CL of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  118. Part I: CL of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  119. Part A: Volume of Distribution After Oral Administration (Vz/F) of Niraparib [ Time Frame: Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  120. Part A: Volume of Distribution After Intravenous Administration (Vz) of of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  121. Part B: Vz of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  122. Part C: Vz/F of Niraparib [ Time Frame: Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  123. Part C: Vz of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  124. Part D: Vz of TSR-042 [ Time Frame: Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  125. Part E: Vz of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  126. Part F: Vz of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  127. Part F: Vz of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  128. Part G: Vz of TSR-042 [ Time Frame: Cycles 1 and 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  129. Part H: Vz of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  130. Part H: Vz of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  131. Part I: Vz of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  132. Part I: Vz of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  133. Part A: AUC at Steady State (AUCss) of Niraparib [ Time Frame: Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  134. Part A: AUCss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  135. Part B: AUCss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  136. Part C: AUCss of Niraparib [ Time Frame: Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  137. Part C: AUCss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  138. Part D: AUCss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  139. Part E: AUCss of TSR-042 [ Time Frame: Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  140. Part F: AUCss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  141. Part F: AUCss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  142. Part G: AUCss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  143. Part H: AUCss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  144. Part H: AUCss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  145. Part I: AUCss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  146. Part I: AUCss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  147. Part A: Ctau at Steady State (Ctau,ss) of Niraparib [ Time Frame: Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  148. Part A: Ctau,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  149. Part B: Ctau,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  150. Part C: Ctau,ss of Niraparib [ Time Frame: Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  151. Part C: Ctau,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  152. Part D: Ctau,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  153. Part E: Ctau,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  154. Part F: Ctau,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  155. Part F: Ctau,ss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  156. Part G: Ctau,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  157. Part H: Ctau,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  158. Part H: Ctau,ss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  159. Part I: Ctau,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  160. Part I: Ctau,ss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  161. Part A: Cmax at Steady State (Cmax,ss) of Niraparib [ Time Frame: Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  162. Part A: Cmax,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  163. Part B: Cmax,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  164. Part C: Cmax,ss of Niraparib [ Time Frame: Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  165. Part C: Cmax,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  166. Part D: Cmax,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  167. Part E: Cmax,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  168. Part F: Cmax,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  169. Part F: Cmax,ss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  170. Part G: Cmax,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  171. Part H: Cmax,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  172. Part H: Cmax,ss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  173. Part I: Cmax,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  174. Part I: Cmax,ss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  175. Part A: Time to Reach Maximum Plasma Concentration (Tmax) of Niraparib [ Time Frame: Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  176. Part A: Tmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  177. Part B: Tmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  178. Part C: Tmax of Niraparib [ Time Frame: Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  179. Part C: Tmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  180. Part D: Tmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  181. Part E: Tmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  182. Part F: Tmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  183. Part F: Tmax of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  184. Part G: Tmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  185. Part H: Tmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  186. Part H: Tmax of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  187. Part I: Tmax of TSR-042 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  188. Part I: Tmax of TSR-022 [ Time Frame: Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  189. Part A: Tmax at Steady State (Tmax,ss) of Niraparib [ Time Frame: Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  190. Part A: Tmax,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  191. Part B: Tmax,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  192. Part C: Tmax,ss of Niraparib [ Time Frame: Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods.

  193. Part C: Tmax,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  194. Part D: Tmax,ss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  195. Part E: Tmax,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  196. Part F: Tmax,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  197. Part F: Tmax,ss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  198. Part G: Tmax,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  199. Part H: Tmax,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  200. Part H: Tmax,ss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  201. Part I: Tmax,ss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  202. Part I: Tmax,ss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  203. Part A: Volume of Distribution After Intravenous Administration (Vss) of of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  204. Part B: Vss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  205. Part C: Vss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  206. Part D: Vss of TSR-042 [ Time Frame: Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  207. Part E: Vss of TSR-042 [ Time Frame: Cycle 2: Pre-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  208. Part F: Vss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods.

  209. Part F: Vss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods.

  210. Part G: Vss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  211. Part H: Vss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  212. Part H: Vss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  213. Part I: Vss of TSR-042 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.

  214. Part I: Vss of TSR-022 [ Time Frame: Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days) ]
    Blood samples were planned to be collected at indicated time points.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has histologically or cytologically proven advanced (unresectable) or metastatic cancer as outlined below according to study part and disease type:
  • Part A: Patients with previously treated advanced or metastatic cancer. Patient may have received no more than 4 lines of treatment for advanced or metastatic cancer. Hormonal treatment will not be considered a prior line of treatment.
  • Part B: Patients with advanced or metastatic cancer for which treatment with carboplatin-paclitaxel is considered appropriate therapy. Patient may have received no more than 1 prior line of chemotherapy in the metastatic setting. Hormonal treatment will not be considered a prior line of treatment.
  • Part C: Patients with previously treated advanced or metastatic cancer. Patient may have received no more than 4 lines of treatment for advanced or metastatic cancer. Hormonal treatment will not be considered a prior line of treatment.
  • Part D: Patients in whom carboplatin-paclitaxel and bevacizumab is considered appropriate therapy. Patient may have received no more than 1 prior line of chemotherapy in the metastatic setting. Hormonal treatment will not be considered a prior line of treatment.
  • Part E and F: Patients who have not received prior systemic therapy, including targeted therapy and biologic agents, for their advanced or metastatic (Stage ≥ IIIB or IV) Non-Squamous NSCLC. Patients who have received neoadjuvant or adjuvant therapy are eligible as long as development of advanced or metastatic disease occurred at least 12 months after completion of neoadjuvant or adjuvant therapy.
  • Part G, H, and I: Patients who have not received prior systemic therapy, including targeted therapy and biologic agents, for their advanced or metastatic (Stage ≥ IIIB or IV) NSCLC. Patients who have received neoadjuvant or adjuvant therapy are eligible as long as development of advanced or metastatic disease occurred at least 12 months after completion of neoadjuvant or adjuvant therapy.
  • Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • Patient has adequate organ function.
  • Female patient has a negative serum pregnancy test within 72 hours prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment, or is of non-childbearing potential.
  • Male patient agrees to use an adequate method of contraception and not donate sperm starting with the first dose of study treatment through 90 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
  • Patient has measurable lesions by RECIST v1.1.

For Part A and C, in addition to the general inclusion criteria, patients must also meet the following additional criterion to be considered eligible to participate in this study:

  • Patient is able to take oral medications.
  • For patients to be eligible for any parts of the study using niraparib 300 mg as a starting dose, a screening actual body weight ≥ 77 kg and screening platelet count ≥ 150,000 u/L is necessary.

Exclusion Criteria: (Patients will not be eligible for the study entry if any of the following criteria are met)

  • Patient has known active central nervous system metastases, carcinomatous meningitis, or both.
  • Patient has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.
  • Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection that requires systemic therapy.
  • Patient has a condition (such as transfusion-dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation
  • Patient is pregnant or expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study treatment.

Note: No data are available regarding the presence of niraparib or its metabolites in human milk, or on its effects on the breastfed infant or milk production. Because of the potential for serious adverse reactions in breastfed infants from niraparib, female patients should not breastfeed during treatment with niraparib and for 1 month after receiving the final dose.

  • Patient has a known history of human immunodeficiency virus (type 1 or 2 antibodies).
  • Patient has known active hepatitis B or hepatitis C.
  • Patient has an active autoimmune disease that has required systemic treatment in the past 2 years.
  • Patient has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
  • Patient has undergone prior treatment with a known PARP inhibitor.
  • Known history or current diagnosis of MDS or AML.
  • Patient has a known hypersensitivity to TSR-042 components or excipients.

For Parts B, D, E, F, G, H, and I, patients will not be eligible for study entry if any of the following additional exclusion criterion are met:

• Patient has a known hypersensitivity to any of the following relevant study treatments: carboplatin, paclitaxel, pemetrexed, nab-paclitaxel, or TSR-022 components or excipients.

For Parts C and D only, patients will not be eligible for study entry if the following additional exclusion criterion is met:

  • Patient has clinically significant cardiovascular disease (e.g., significant cardiac conduction abnormalities, uncontrolled hypertension, myocardial infarction, cardiac arrhythmia or unstable angina, New York Heart Association Grade 2 or greater congestive heart failure, serious cardiac arrhythmia requiring medication, Grade 2 or greater peripheral vascular disease, and history of cerebrovascular accident [CVA]) within 6 months of enrollment.
  • Patient has a history of bowel obstruction, including subocclusive disease, related to the underlying disease and history of abdominal fistula, gastrointestinal perforation, or intra abdominal abscesses. Evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.
  • Patient has proteinuria as demonstrated by urine protein: creatinine ratio ≥1.0 at screening or urine dipstick for proteinuria ≥2 (patients discovered to have ≥2 proteinuria on dipstick at baseline should undergo 24-hour urine collection and must demonstrate <2 g of protein in 24 hours to be eligible).
  • Patient is at increased bleeding risk due to concurrent conditions (e.g., major injuries or surgery within the past 28 days prior to start of study treatment, history of hemorrhagic stroke, transient ischemic attack, subarachnoid hemorrhage, or clinically significant hemorrhage within the past 3 months).
  • Patient has a known hypersensitivity to bevacizumab components or excipients.

For Parts E and F only, patients will not be eligible for study entry if any of the following additional exclusion criteria are met:

  • Patient is unable to interrupt aspirin or other nonsteroidal ant-inflammatory drugs, other than an aspirin dose ≤ 1.3 g per day, for a 5-day period (8-day period for long -acting agents, such as piroxicam.
  • Patient is unable or unwilling to take folic acid, vitamin B12 supplement.
  • Patient has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.

For Parts G, H, and I only, patients will not be eligible for study entry if any of the following additional exclusion criteria are met:

• Patient has pre-existing peripheral neuropathy that is Grade ≥ 2 by Common Terminology Criteria for Adverse Events (CTCAE) version 4 criteria.

For Parts E, F, G, H and I only, patients will not be eligible for study entry if any of the following additional exclusion criteria are met:

• Patient has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03307785


Locations
Layout table for location information
United States, Arizona
GSK Investigational Site
Scottsdale, Arizona, United States, 85258
United States, California
GSK Investigational Site
Encinitas, California, United States, 92024
United States, Florida
GSK Investigational Site
Sarasota, Florida, United States, 34232
United States, Ohio
GSK Investigational Site
Canton, Ohio, United States, 44718
GSK Investigational Site
Cleveland, Ohio, United States, 44106
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
GSK Investigational Site
Houston, Texas, United States, 77030
Sponsors and Collaborators
Tesaro, Inc.
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
  Study Documents (Full-Text)

Documents provided by Tesaro, Inc.:
Study Protocol  [PDF] August 15, 2018
Statistical Analysis Plan  [PDF] September 18, 2020

Layout table for additonal information
Responsible Party: Tesaro, Inc.
ClinicalTrials.gov Identifier: NCT03307785    
Other Study ID Numbers: 213351
3000-01-002 ( Other Identifier: Tesaro )
First Posted: October 12, 2017    Key Record Dates
Results First Posted: May 10, 2021
Last Update Posted: May 10, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neoplastic Processes
Pathologic Processes
Paclitaxel
Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Pemetrexed
Niraparib
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs